Therefore, to assess the impact of BCR phosphoprotein activation on MCL patients’ outcome we investigated time-to-event modeling for PFS and OS using both BCR signaling data in the anti-IgM-modulated condition as continuous variables and the available known prognostic parameters (i.e., age, LDH, WBC count, forms/morphological variants, Ki-67, SOX11, MIPI categories). This evidence concerns the gene MKI67 and mantle cell lymphoma.